New facets of antifungal therapy

References

• Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal pipeline. Science 2015; 347:1414-6; PMID:25814567
   PubMedGoogle Scholar
• Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-96; PMID:23245607; http://dx.doi.org/10.1016/S0140-6736(12)61729-2
   PubMed Web of Science ®Google Scholar
• Perfect JR, Hachem R, Wingard JR. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin Infect Dis 2014; 59 Suppl 5:S352-5; PMID:25352630; http://dx.doi.org/10.1093/cid/ciu639
   PubMedGoogle Scholar
• Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217-23; PMID:16206093; http://dx.doi.org/10.1086/496991
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801-12; PMID:18462107; http://dx.doi.org/10.1086/588300
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807-25; PMID:17806045; http://dx.doi.org/10.1086/521259
   PubMed Web of Science ®Google Scholar
• Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 2014; 4:a019703; http://dx.doi.org/10.1101/cshperspect.a019703
   PubMed Web of Science ®Google Scholar
• Pana ZD, Kougia V, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. Expert Opin Pharmacother 2015; 16:693-710; PMID:25676454; http://dx.doi.org/10.1517/14656566.2015.1013936
   PubMed Web of Science ®Google Scholar
• Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf 2015; 14:325-34; PMID:25409549; http://dx.doi.org/10.1517/14740338.2015.983071
   PubMed Web of Science ®Google Scholar
• Chitasombat MN, Kontoyiannis DP. The ‘cephalosporin era’ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opin Pharmacother 2015; 16:1543-58; PMID:26100603; http://dx.doi.org/10.1517/14656566.2015.1057500
   PubMed Web of Science ®Google Scholar
• Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother 2015; 49:825-42; PMID:25940222; http://dx.doi.org/10.1177/1060028015581679
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Verweij PE, Mouton JW. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Rev Anti Infect Ther 2015; 13:9-27; http://dx.doi.org/10.1586/14787210.2015.990382
   PubMed Web of Science ®Google Scholar
• Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence 2016; 1-17; PMID:27268286; http://dx.doi.org/10.1080/21505594.2016.1196300
   PubMedGoogle Scholar
• Greenblatt HK, Greenblatt DJ. Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 2014; 54:1321-9; PMID:25216238; http://dx.doi.org/10.1002/jcph.400
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12:40-79
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47:779-92; PMID:19026034; http://dx.doi.org/10.2165/0003088-200847120-00003
   PubMed Web of Science ®Google Scholar
• Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263-72; http://dx.doi.org/10.1056/NEJM199401273300407
   PubMed Web of Science ®Google Scholar
• Maertens J. History of the development of azole derivatives. Clin Microbiol Infect 2004; 10:1-10; http://dx.doi.org/10.1111/j.1470-9465.2004.00841.x
   PubMed Web of Science ®Google Scholar
• Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Microbiol Rep 2015; 2:84-95; PMID:26120512; http://dx.doi.org/10.1007/s40588-015-0015-1
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46:120-8; http://dx.doi.org/10.1086/524071
   PubMed Web of Science ®Google Scholar
• Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med 2016; 3:1-10; PMID:27014694; http://dx.doi.org/10.3389/fmed.2016.00011
   PubMed Web of Science ®Google Scholar
• Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 2013; 26:493-500; PMID:24126719; http://dx.doi.org/10.1097/QCO.0000000000000005
   PubMed Web of Science ®Google Scholar
• Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin 2013; 29 Suppl 4:13-8; PMID:23621589; http://dx.doi.org/10.1185/03007995.2012.761135
   PubMed Web of Science ®Google Scholar
• Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am 2016; 30:51-83; PMID:26739608; http://dx.doi.org/10.1016/j.idc.2015.10.012
   PubMed Web of Science ®Google Scholar
• Trofe-Clark J, Lemonovich TL. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation. Am J Transplant 2013; 13:318-26; PMID:23465024; http://dx.doi.org/10.1111/ajt.12123
   PubMed Web of Science ®Google Scholar
• Elbey MA, Cil H, Onturk E, Islamoglu Y. QTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy. Eur Rev Med Pharmacol Sci 2012; 16:100-2; PMID:22338554
   PubMed Web of Science ®Google Scholar
• Pham CP, de Feiter PW, Van der Kuy PHM, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006; 40:1456-61; PMID:16849620; http://dx.doi.org/10.1345/aph.1G741
   PubMed Web of Science ®Google Scholar
• Brown JD, Lim LL, Koning S. Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. Med Mycol Case Rep 2014; 4:23-5; PMID:24855597; http://dx.doi.org/10.1016/j.mmcr.2014.03.001
   PubMedGoogle Scholar
• Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610-7; PMID:18190324 ; http://dx.doi.org/10.1086/523576
   PubMed Web of Science ®Google Scholar
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009; 18:1279-95; PMID:19678798; http://dx.doi.org/10.1517/13543780903176407
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america. Clin Infect Dis 2015; 62:e1-50; PMID:26679628
   PubMedGoogle Scholar
• Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-22; PMID:22412055; http://dx.doi.org/10.1093/cid/cis021
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42:1862-5; PMID:9661037
   PubMed Web of Science ®Google Scholar
• Allen D, Wilson D, Drew R, Perfect J. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Anti Infect Ther 2015; 13:787-98; http://dx.doi.org/10.1586/14787210.2015.1032939
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. Triazole antifungal agents in invasive fungal infections. Drugs 2011; 71:2405-19; http://dx.doi.org/10.2165/11596540-000000000-00000
   PubMed Web of Science ®Google Scholar
• Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent. Ecancermedicalscience 2015; 9:521; PMID:25932045
   PubMed Web of Science ®Google Scholar
• Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 1999; 22:1355-9; PMID:10746169; http://dx.doi.org/10.1248/bpb.22.1355
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15; PMID:12167683 ; http://dx.doi.org/10.1056/NEJMoa020191
   PubMed Web of Science ®Google Scholar
• McKeage K. Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. Drugs 2015; 75:397-406; PMID:25595699; http://dx.doi.org/10.1007/s40265-015-0348-3
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67:2725-30; PMID:22833639; http://dx.doi.org/10.1093/jac/dks268
   PubMed Web of Science ®Google Scholar
• Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother 2015; 59:4424-8; PMID:25987632; http://dx.doi.org/10.1128/AAC.00581-15
   PubMed Web of Science ®Google Scholar
• Pham AN, Bubalo JS, Lewis JS. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses 2016; 59:226-33; http://dx.doi.org/10.1111/myc.12452
   PubMed Web of Science ®Google Scholar
• Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother 2015; 59:4914-8; PMID:26055378; http://dx.doi.org/10.1128/AAC.00496-15
   PubMed Web of Science ®Google Scholar
• Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014; 58:3610-7; PMID:24733463; http://dx.doi.org/10.1128/AAC.02686-13
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approvals for the first 6 months of 2015. Nat Rev Drug Discov 2015; 14:517
   Web of Science ®Google Scholar
• Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacother 2015; 35:1037-51; PMID:26598096; http://dx.doi.org/10.1002/phar.1652
   PubMed Web of Science ®Google Scholar
• Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012; 8:759-65; PMID:22530880; http://dx.doi.org/10.1517/17425255.2012.683859
   PubMed Web of Science ®Google Scholar
• Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015; 61:1558-65; PMID:26179012; http://dx.doi.org/10.1093/cid/civ571
   PubMed Web of Science ®Google Scholar
• Thompson GR, 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313; http://dx.doi.org/10.1007/s11046-010-9324-3
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis 2015; 82:303-13; PMID:25986029; http://dx.doi.org/10.1016/j.diagmicrobio.2015.04.008
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013; 51:2608-16; PMID:23740727 ; http://dx.doi.org/10.1128/JCM.00863-13
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162-76; http://dx.doi.org/10.1093/jac/dkt508
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:2806-13; PMID:22391534 ; http://dx.doi.org/10.1128/AAC.05900-11
   PubMed Web of Science ®Google Scholar
• Neofytos D, Ostrander D, Shoham S, Laverdiere M, Hiemenz J, Nguyen H, Clarke W, Brass L, Lu N, Marr KA. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. Transpl Infect Dis 2015; 17:831-7; PMID:26346408 ; http://dx.doi.org/10.1111/tid.12454
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24-34; PMID:18955533; http://dx.doi.org/10.1128/AAC.00705-08
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12; http://dx.doi.org/10.1086/508774
   PubMed Web of Science ®Google Scholar
• van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, Kosterink JG, Span LF, Alffenaar JW. Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Ther Drug Monit 2015; 37:766-71; PMID:26565789; http://dx.doi.org/10.1097/FTD.0000000000000235
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56:5503-10; PMID:22890761; http://dx.doi.org/10.1128/AAC.00802-12
   PubMed Web of Science ®Google Scholar
• Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jimenez JL, Candoni A, Raad I, Laverdiere M, Langston A, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 2016; 71:718-26; PMID:26612870 ; http://dx.doi.org/10.1093/jac/dkv380
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55:1080-7; PMID:22761409; http://dx.doi.org/10.1093/cid/cis599
   PubMed Web of Science ®Google Scholar
• Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother 2016; 71:1786-99; http://dx.doi.org/10.1093/jac/dkw099
   PubMed Web of Science ®Google Scholar
• Karthaus M, Lehrnbecher T, Lipp HP, Kluge S, Buchheidt D. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach. Ann Hematol 2015; 94:547-56; PMID:25697592; http://dx.doi.org/10.1007/s00277-015-2333-z
   PubMed Web of Science ®Google Scholar
• Hoy Z, Dodds Ashley ES, Weinberg GA, Krysan DJ. Voriconazole therapeutic drug monitoring. J Pediatric Infect Dis Soc 2014; 3:270-1; http://dx.doi.org/10.1093/jpids/piu019
   PubMedGoogle Scholar
• Pitman SK, Drew RH, Perfect JR. Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin Emerg Drugs 2011; 16:559-86; http://dx.doi.org/10.1517/14728214.2011.607811
   PubMed Web of Science ®Google Scholar
• Kamiński DM. Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. Eur Biophys J 2014; 43:453-67; PMID:25173562; http://dx.doi.org/10.1007/s00249-014-0983-8
   PubMed Web of Science ®Google Scholar
• Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 2012; 109:2234-9; PMID:22308411; http://dx.doi.org/10.1073/pnas.1117280109
   PubMed Web of Science ®Google Scholar
• Kovacic P, Cooksy A. Novel, unifying mechanism for amphotericin B and other polyene drugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action. MedChemComm 2012; 3:274-80; http://dx.doi.org/10.1039/C2MD00267A
   Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011; 86:805-17; PMID:21803962 ; http://dx.doi.org/10.4065/mcp.2011.0247
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71; PMID:10072411; http://dx.doi.org/10.1056/NEJM199903113401004
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96; PMID:9636868; http://dx.doi.org/10.1086/516353
   PubMed Web of Science ®Google Scholar
• Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis 2013; 76:361-7; http://dx.doi.org/10.1016/j.diagmicrobio.2013.04.001
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73:919-34; http://dx.doi.org/10.1007/s40265-013-0069-4
   PubMed Web of Science ®Google Scholar
• Davis SA, Vincent BM, Endo MM, Whitesell L, Marchillo K, Andes DR, Lindquist S, Burke MD. Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 2015; 11:481-7; PMID:26030729; http://dx.doi.org/10.1038/nchembio.1821
   PubMed Web of Science ®Google Scholar
• Wilcock BC, Endo MM, Uno BE, Burke MD. C2′-OH of amphotericin B plays an important role in binding the primary sterol of human cells but not yeast cells. J Am Chem Soc 2013; 135:8488-91; PMID:23718627 ; http://dx.doi.org/10.1021/ja403255s
   PubMed Web of Science ®Google Scholar
• Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet 2015; 16:459-71; PMID:26149714; http://dx.doi.org/10.1038/nrg3922
   PubMed Web of Science ®Google Scholar
• Pemán J, Cantón E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009; 7:453-60; http://dx.doi.org/10.1586/eri.09.18
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3-S13; PMID:22196207; http://dx.doi.org/10.1016/j.amjmed.2011.11.001
   PubMed Web of Science ®Google Scholar
• Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur J Med Res 2011; 16:159-66; PMID:21486730; http://dx.doi.org/10.1186/2047-783X-16-4-159
   PubMed Web of Science ®Google Scholar
• Stover KR, Farley JM, Kyle PB, Cleary JD. Cardiac toxicity of some echinocandin antifungals. Expert Opin Drug Saf 2014; 13:5-14; PMID:24047086 ; http://dx.doi.org/10.1517/14740338.2013.829036
   PubMed Web of Science ®Google Scholar
• Moriyama B, Gordon LA, McCarthy M, Henning SA, Walsh TJ, Penzak SR. Emerging drugs and vaccines for candidemia. Mycoses 2014; 57:718-33; PMID:25294098 ; http://dx.doi.org/10.1111/myc.12265
   PubMed Web of Science ®Google Scholar
• Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, et al. Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2011; 55:5099-106; PMID:21844320; http://dx.doi.org/10.1128/AAC.00432-11
   PubMed Web of Science ®Google Scholar
• Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P, Sternad-Klobschauer K, Habernig E, Wandschneider W, Grimm G. A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 2013; 38:241-2; PMID:23550735 ; http://dx.doi.org/10.1111/jcpt.12046
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013; 16:81-95; PMID:24618110 ; http://dx.doi.org/10.1016/j.drup.2014.01.001
   PubMed Web of Science ®Google Scholar
• Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51:513-21; PMID:12615851 ; http://dx.doi.org/10.1093/jac/dkg117
   PubMed Web of Science ®Google Scholar
• Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015; 1354:1-11; PMID:26190298; http://dx.doi.org/10.1111/nyas.12831
   PubMed Web of Science ®Google Scholar
• Johnson ME, Katiyar SK, Edlind TD. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother 2011; 55:3774-81; PMID:21576441 ; http://dx.doi.org/10.1128/AAC.01811-10
   PubMed Web of Science ®Google Scholar
• Muilwijk EW, Lempers VJC, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ. Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther 2015; 13:799-815; PMID:25947367; http://dx.doi.org/10.1586/14787210.2015.1028366
   PubMed Web of Science ®Google Scholar
• Saner F, Gensicke J, Rath P, Fruhauf N, Gu Y, Paul A, Radtke A, Malagó M, Broelsch C. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34:328-32; PMID:17180587; http://dx.doi.org/10.1007/s15010-006-5657-8
   PubMed Web of Science ®Google Scholar
• Undre NA, Stevenson P, Wilbraham D. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects. Int J Clin Pharmacol Ther 2014; 52:237-44; http://dx.doi.org/10.5414/CP202015
   PubMed Web of Science ®Google Scholar
• NCT02267382. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis. 2014. 12-02-2015.
   Google Scholar
• NCT01891331. A phase 2a, randomized, double-blind, dose ranging study to evaluate the efficacy and safety of VT-1161 oral tablets compared to fluconazole in the treatment of patients with moderate to severe acute vulvovaginal candidiasis. 2013. 12-22-2014
   Google Scholar
• Warrilow AGS, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother 2014; 58:7121-7; PMID:25224009; http://dx.doi.org/10.1128/AAC.03707-14
   PubMed Web of Science ®Google Scholar
• Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL, Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother 2015; 59:5567-73; PMID:26124165 ; http://dx.doi.org/10.1128/AAC.00185-15
   PubMed Web of Science ®Google Scholar
• Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 2015; 59:4308-11; PMID:25896696 ; http://dx.doi.org/10.1128/AAC.00234-15
   PubMed Web of Science ®Google Scholar
• NCT02244606. Oral SCY-078 vs standard-of-care following IV echinocandin in the treatment of invasive candidiasis. 2014. 11-12-2015
   Google Scholar
• Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother 2015; 59:1265-72; PMID:25512406 ; http://dx.doi.org/10.1128/AAC.04445-14
   PubMed Web of Science ®Google Scholar
• Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 2014; 58:1248-51; PMID:24323472 ; http://dx.doi.org/10.1128/AAC.02145-13
   PubMed Web of Science ®Google Scholar
• Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317:334-41; PMID:3299095; http://dx.doi.org/10.1056/NEJM198708063170602
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301:126-31; PMID:449951; http://dx.doi.org/10.1056/NEJM197907193010303
   PubMed Web of Science ®Google Scholar
• Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008; 61:i41-4; http://dx.doi.org/10.1093/jac/dkm426
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Cervera C, Hoyo I, Linares L, Sanclemente G, Bosch J, Marco F, Cofán F, Ricart MJ, Navasa M, et al. Incidence and outcome of early Candida peritonitis after liver and pancreas transplantation. Mycoses 2013; 56:162-7; PMID:22897802; http://dx.doi.org/10.1111/j.1439-0507.2012.02227.x
   PubMed Web of Science ®Google Scholar
• Sarkar S, Uppuluri P, Pierce CG, Lopez-Ribot JL. In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother 2014; 58:1183-6; PMID:24217700; http://dx.doi.org/10.1128/AAC.01745-13
   PubMed Web of Science ®Google Scholar
• Storm L, Lausch KR, Arendrup MC, Mortensen KL, Petersen E. Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. Med Mycol Case Rep 2014; 6:6-9; PMID:25379389; http://dx.doi.org/10.1016/j.mmcr.2014.07.001
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60; PMID:18177225; http://dx.doi.org/10.1086/525258
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162:81-9; PMID:25599346; http://dx.doi.org/10.7326/M13-2508
   PubMed Web of Science ®Google Scholar
• Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents 2015; 45:283-8; PMID:25455847; http://dx.doi.org/10.1016/j.ijantimicag.2014.08.012
   PubMed Web of Science ®Google Scholar
• Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011; 54:39-44; PMID:21126271; http://dx.doi.org/10.1111/j.1439-0507.2010.01985.x
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46:171-9; PMID:10933638; http://dx.doi.org/10.1093/jac/46.2.171
   PubMed Web of Science ®Google Scholar
• Perfect JR. Efficiently killing a sugar-coated yeast. N Engl J Med 2013; 368:1354-6; PMID:23550675; http://dx.doi.org/10.1056/NEJMe1302038
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322; PMID:20047480; http://dx.doi.org/10.1086/649858
   PubMed Web of Science ®Google Scholar
• Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:1291-302; PMID:23550668; http://dx.doi.org/10.1056/NEJMoa1110404
   PubMed Web of Science ®Google Scholar
• Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, Bishop L, Rebe K, Williams A, Jaffar S, Bekker LG, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54:121-8; PMID:22052885; http://dx.doi.org/10.1093/cid/cir745
   PubMed Web of Science ®Google Scholar
• Krysan DJ. Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs. Fungal Genet Biol 2015; 78:93-8; PMID:25514636; http://dx.doi.org/10.1016/j.fgb.2014.12.001
   PubMed Web of Science ®Google Scholar
• Ogawa T, Takezawa K, Tojima I, Shibayama M, Kouzaki H, Ishida M, Okabe H, Shimizu T. Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Auris Nasus Larynx 2012; 39:224-8; PMID:21592699; http://dx.doi.org/10.1016/j.anl.2011.03.006
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fätkenheuer G, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39:310-24; PMID:22917084; http://dx.doi.org/10.3109/1040841X.2012.711741
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect 2016; 22:811; http://dx.doi.org/10.1016/j.cmi.2016.03.029
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, Edwards J, Filler SG, Goldberg R, Spellberg B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47:364-71; PMID:18558882; http://dx.doi.org/10.1086/589857
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 36:1619-22; PMID:12802765; http://dx.doi.org/10.1086/375235
   PubMed Web of Science ®Google Scholar
• Dickson EC. “Valley Fever” of the San Joaquin Valley and fungus Coccidioides. Cal West Med 1937; 47:151-5; PMID:18744202
   PubMedGoogle Scholar
• Park DW, Sohn JW, Cheong HJ, Kim WJ, Kim MJ, Kim JH, Shin C. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect Dis 2006; 6:26; PMID:16480497; http://dx.doi.org/10.1186/1471-2334-6-26
   PubMed Web of Science ®Google Scholar
• Levy ER, McCarty JM, Shane AL, Weintrub PS. Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series. Clin Infect Dis 2013; 56:1573-8; PMID:23463636; http://dx.doi.org/10.1093/cid/cit113
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35; PMID:19191635; http://dx.doi.org/10.1086/596757
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42:1171-8; http://dx.doi.org/10.1086/501020
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. Bone Marrow Transplant 2011; 46:709-18; PMID:20661235; http://dx.doi.org/10.1038/bmt.2010.175
   PubMed Web of Science ®Google Scholar
• Krishna G, Vickery D, Ma L, Yu X, Noren C, Power E, Beresford E, Medlock M. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. J Clin Pharmacol 2011; 51:84-92; PMID:20489029; http://dx.doi.org/10.1177/0091270009360982
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49:1331-6; PMID:15793107; http://dx.doi.org/10.1128/AAC.49.4.1331-1336.2005
   PubMed Web of Science ®Google Scholar